New England Journal of Medicine published a clinical update in Research Highlights on 01 Apr 2026. The item focuses on CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia. Review the original article for the full source wording and details.
New England Journal of Medicine published a clinical update in Research Highlights on 01 Apr 2026.
The item focuses on CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia.
Review the original article for the full source wording and details.